Novo Nordisk shares hit 4-year low, Trump urges US drug price cuts

Novo Nordisk (NOVOb.CO) shares fell around 4% on Friday, reaching a four-year low and contributing to its worst-ever weekly loss of over 30%. This decline was primarily driven by U.S. President Donald Trump's push for drug price cuts, exacerbating investor concerns following the company's recently slashed 2025 sales growth outlook and new CEO appointment.

Analysis

Novo Nordisk (NOVOb.CO) is facing a severe confluence of negative catalysts, culminating in a historic weekly share price decline of over 30%. The immediate pressure, a 4% drop on Friday, brought the stock to a four-year low and was directly triggered by U.S. political intervention, as President Donald Trump formally urged pharmaceutical firms to lower drug prices. This introduces significant regulatory and pricing uncertainty in a key market. This political headwind exacerbates an already fragile investor sentiment, following the company's recent decision to slash its 2025 sales growth outlook. The concurrent appointment of a new CEO, Maziar Mike Doustdar, amidst this turmoil further amplifies uncertainty regarding future strategic direction and the company's ability to navigate these compounding challenges.

Key Decisions for Investors

• Given the combination of a severe guidance cut, leadership transition, and acute political pressure on U.S. pricing, investors should recognize the significantly elevated risk profile and the potential for further volatility.
• Closely monitor any statements from the new CEO regarding strategic pivots and the company's formal response to U.S. pricing pressures, as these will be critical indicators for future margin stability.
• Despite the historic sell-off, entering a new position is highly speculative until there is greater clarity on the long-term earnings impact of both the revised guidance and potential U.S. price concessions.